Clevidipine
Who holds supplier records for Clevidipine? 3 organisations hold a current record for Clevidipine: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: France (1), United Kingdom (1) and China (1).
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Clevidipine: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/clevidipine
Reading the evidence
- 3 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- No company-level GMP certificate matched
No current EU or UK GMP certificate was matched to these organisations. That is not a negative finding; ask each candidate for its certificate and latest inspection outcome.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Clevidipine expires 10 Oct 2031. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (3)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Clevidipine. Country is the organisation's recorded country, not necessarily the manufacturing site.
- CHEMWERTH INCFranceActive DMF 34556 · latest filing Jun 2020
- VERANOVA LPUnited KingdomActive DMF 16771 · latest filing Aug 2003
- YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTDChinaActive DMF 44594 · latest filing Aug 2026
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Clevidipine). The latest listed patent expires 10 Oct 2031. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Overview
Clevidipine is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL1237132).
Chemical identity
- IUPAC name
- 5-O-(butanoyloxymethyl) 3-O-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
- Canonical SMILES
- CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C
- InChIKey
- KPBZROQVTHLCDU-UHFFFAOYSA-N
- Synonyms
- Clevidepine, Clevidepine butyrate, Clevidipine, Clevidipino, Cleviprex, H-324/38, H324/38, Clevelox, clevidipinum, clevipidine, RefChem:57329, C08CA16
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Dihydropyridine Calcium Channel Blocker
- Mechanism of action
- Calcium Channel Antagonists
- Chemical structure
- Dihydropyridines
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Clevidipine?
3 organisations hold an active US FDA Type II Drug Master File or a CEP for Clevidipine: CHEMWERTH INC (France), VERANOVA LP (United Kingdom) and YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (China). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Clevidipine Drug Master Files are active?
CHEMWERTH INC (DMF 34556), VERANOVA LP (DMF 16771) and YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU HAICI BIOLOGICAL PHARMACEUTICAL CO LTD (DMF 44594). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
Does the FDA Orange Book list patents for products containing Clevidipine?
Yes. The latest patent listed for an approved US product containing Clevidipine expires 10 Oct 2031, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Clevidipine supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Clevidipine?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.